Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal cenegermin for acute non-arteritic anterior ischemic optic neuropathy
2025-524748-37-00Phase 2Authorised
- Sponsor
- Dompé
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in non-arteritic anterior ischemic optic neuropathy (NAION) comparing Intranasal cenegermin with Vehicle control (2 arms). Primary endpoint: Improvement in best corrected visual acuity responder rate. Planned start Sep 2026; status: authorised.
02
Drugs
cenegermin
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2025-524748-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524748-37-00.